Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
Authors
D'Amico, Anthony VChen, Ming-Hui
Crook, Juanita
Armstrong, John G
Malone, Shawn
Steigler, Allison
Dunne, Mary
Kantoff, Philip W
Denham, James W
Affiliation
Brigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.orgIssue Date
2011-12-10MeSH
AgedAndrogen Antagonists
Antineoplastic Agents, Hormonal
Cohort Studies
Combined Modality Therapy
Humans
Male
Neoplasm Staging
Prognosis
Prostatic Neoplasms
Treatment Outcome
Metadata
Show full item recordCitation
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.Journal
Journal of clinical oncology : official journal of the American Society of Clinical OncologyDOI
10.1200/JCO.2011.37.0726PubMed ID
22042952Abstract
We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.Item Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2011.37.0726